The Conversation (0)
March 17, 2025
21 May 2024
Cleo Diagnostics
Revolutionising Ovarian Cancer Diagnosis Through Accurate and Early Detection Keep Reading...
27 February
Appendix 4D and Half Yearly Accounts
Cleo Diagnostics (COV:AU) has announced Appendix 4D and Half Yearly AccountsDownload the PDF here. Keep Reading...
31 January
Quarterly activities and cashflow report
Cleo Diagnostics (COV:AU) has announced Quarterly activities and cashflow reportDownload the PDF here. Keep Reading...
09 December 2024
CLEO Further Expands Ovarian Cancer Trial with Siles Health
Cleo Diagnostics (COV:AU) has announced CLEO Further Expands Ovarian Cancer Trial with Siles HealthDownload the PDF here. Keep Reading...
26 November 2024
The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
Cleo Diagnostics (COV:AU) has announced The Royal Women's Hospital Joins CLEO Ovarian Cancer TrialDownload the PDF here. Keep Reading...
02 December
Invion Secures Expanded Photosoft Global Exclusive License
Invion Limited (IVX:AU) has announced Invion Secures Expanded Photosoft Global Exclusive LicenseDownload the PDF here. Keep Reading...
01 December
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidence that CardiolRx™ reduces inflammation-driven... Keep Reading...
25 November
Transforming Disease Detection with AI-Driven Biological Insights
Artificial intelligence (AI) is fundamentally reshaping biotechnology and healthcare, unlocking the secrets hidden within complex biological data. Machine learning in genomics and proteomics is transforming how diseases are detected, monitored and treated. Central to this revolution are... Keep Reading...
13 November
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market.This allowance fortifies Cardiol's... Keep Reading...
05 November
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume... Keep Reading...
30 October
Appendix 4C and Quarterly Activities Report - September 2025
Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00